Juerg Steiger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juerg Steiger has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Wehmeier
Clinic for Transplantation Immunology and Nephrology University Hospital Basel Basel Switzerland
2 shared publications - Patricia Hirt-Minkowski
Clinic for Transplantation Immunology and Nephrology, University Hospital, Basel, Switzerland
2 shared publications - Alexander Ritter
Division of Nephrology, University Hospital Zurich, Zurich, Switzerland
1 shared publication Céline Fontana
Clinic for Transplantation Immunology and Nephrology, University Hospital, Basel, Switzerland
1 shared publicationDaniel Sidler
Department for Nephrology and Hypertension, University Hospital Insel, Berne, Switzerland
1 shared publication- Deborah Buess
Swiss Organ Living-Donor Health Registry (SOL-DHR), University Hospital Basel, Basel, Switzerland
1 shared publication
Latest Publications
- Open Access
- 5 June 2025
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 155 (6) , 4409
Bleeding risk after native and transplant kidney biopsy – a single-centre observational study
STUDY AIM: Renal biopsies provide important and decisive information for diagnosis and therapy. Although biopsies are considered safe, bleeding complications remain a concern. We analysed the complication rate after kidney biopsies in native and transplant kidneys and their association with platelet function analyser bleeding time (PFA BT) and estimated glomerular filtration rate (eGFR). METHODS: This single-centre observational study included all patients who underwent an ultrasound-guided kidney biopsy at the University Hospital Basel from 2015 to August 2019. The main objective was to investigate the association of PFA BT with significant bleeding complications in kidney biopsies. Significant bleeding was defined as a haemoglobin decrease of >10 g/l within 48 hours or the need for transfusion after bleeding, according to the discretion of the treating physician. The pre-biopsy assessment included bleeding time using PFA BT, INR, thrombocyte count, and eGFR. RESULTS: A total of 819 kidney biopsies—285 native and 534 transplant—were analysed. Complications occurred in 32 biopsies (3.9%): 18 (6.3%) in native and 14 (2.6%) in transplant kidneys. Bleeding was the most frequent complication in both groups. Overall, low eGFR (p = 0.01) and prolonged PFA BT (p = 0.02) were associated with bleeding complications. In native kidney biopsies, inpatient biopsy was associated with bleeding complications (p = 0.005), while in transplant kidney biopsies, bleeding complications were associated with time after transplantation (p <0.001), prolonged PFA BT (p <0.001), and diagnostic biopsies (p = 0.01). In the multivariable model, low eGFR was the only significant factor associated with bleeding complications (odds ratio 3.57, 95% confidence interval 1.76-7.23, p <0.001). CONCLUSIONS: A low eGFR, especially below 30 ml/min, is associated with increased bleeding risk in native and transplant kidney biopsies.
- 5 June 2025
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 155 (6) , 4409
Open AccessBleeding risk after native and transplant kidney biopsy – a single-centre observational study
STUDY AIM: Renal biopsies provide important and decisive information for diagnosis and therapy. Although biopsies are considered safe, bleeding complications remain a concern. We analysed the complication rate after kidney biopsies in native and transplant kidneys and their association with platelet function analyser bleeding time (PFA BT) and estimated glomerular filtration rate (eGFR). METHODS: This single-centre observational study included all patients who underwent an ultrasound-guided kidney biopsy at the University Hospital Basel from 2015 to August 2019. The main objective was to investigate the association of PFA BT with significant bleeding complications in kidney biopsies. Significant bleeding was defined as a haemoglobin decrease of >10 g/l within 48 hours or the need for transfusion after bleeding, according to the discretion of the treating physician. The pre-biopsy assessment included bleeding time using PFA BT, INR, thrombocyte count, and eGFR. RESULTS: A total of 819 kidney biopsies—285 native and 534 transplant—were analysed. Complications occurred in 32 biopsies (3.9%): 18 (6.3%) in native and 14 (2.6%) in transplant kidneys. Bleeding was the most frequent complication in both groups. Overall, low eGFR (p = 0.01) and prolonged PFA BT (p = 0.02) were associated with bleeding complications. In native kidney biopsies, inpatient biopsy was associated with bleeding complications (p = 0.005), while in transplant kidney biopsies, bleeding complications were associated with time after transplantation (p <0.001), prolonged PFA BT (p <0.001), and diagnostic biopsies (p = 0.01). In the multivariable model, low eGFR was the only significant factor associated with bleeding complications (odds ratio 3.57, 95% confidence interval 1.76-7.23, p <0.001). CONCLUSIONS: A low eGFR, especially below 30 ml/min, is associated with increased bleeding risk in native and transplant kidney biopsies.
- Open Access
- 1 June 2025
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 155 (6) , 4513
Metabolic risk after living kidney donation: an analysis of the Swiss Organ Living-Donor Health Registry
BACKGROUND: Due to persistent organ shortage, the selection criteria for living kidney donors have broadened to include elderly donors and those with co-morbidities. As little is known about metabolic health after living kidney donation, this prospective, multicentre cohort study explored metabolic changes among living kidney donors, with a particular focus on weight trajectories. METHODS: We analysed metabolic and cardiovascular parameters before and after living kidney donation in 466 consecutive living kidney donors recorded in the Swiss Organ Living-Donor Health Registry between January 2018 and August 2022. Outcomes included weight, blood pressure, haemoglobin A1c (HbA1c) levels, and the occurrence of new-onset type 2 diabetes mellitus, arterial hypertension and cardiovascular diseases. Donors were stratified by predonation body mass index (BMI) and by postdonation weight change. RESULTS: Obese donors (BMI ≥30 kg/m²) more frequently had pre-existing hypertension at baseline than non-obese donors (31.6% vs 18.3%, p = 0.03). During follow-up (median 2.9 years), 6% of living kidney donors developed arterial hypertension, 2.6% developed cardiovascular diseases and 1.1% developed type 2 diabetes mellitus. Obese donors had a higher incidence of postdonation type 2 diabetes mellitus than non-obese donors (p = 0.01). Changes in BMI postdonation were not correlated with age or predonation BMI. Donors with postdonation weight gain had slightly higher follow-up blood pressure, but no clear differences in rates of new-onset hypertension or type 2 diabetes mellitus were observed between weight-change groups. CONCLUSIONS: This exploratory analysis suggests that living kidney donation is generally metabolically safe. While metabolic changes were modest overall, obesity at the time of donation was associated with a slightly higher frequency of postdonation type 2 diabetes mellitus, underscoring the importance of counselling on lifestyle modification before donation.
- 1 June 2025
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 155 (6) , 4513
Open AccessMetabolic risk after living kidney donation: an analysis of the Swiss Organ Living-Donor Health Registry
BACKGROUND: Due to persistent organ shortage, the selection criteria for living kidney donors have broadened to include elderly donors and those with co-morbidities. As little is known about metabolic health after living kidney donation, this prospective, multicentre cohort study explored metabolic changes among living kidney donors, with a particular focus on weight trajectories. METHODS: We analysed metabolic and cardiovascular parameters before and after living kidney donation in 466 consecutive living kidney donors recorded in the Swiss Organ Living-Donor Health Registry between January 2018 and August 2022. Outcomes included weight, blood pressure, haemoglobin A1c (HbA1c) levels, and the occurrence of new-onset type 2 diabetes mellitus, arterial hypertension and cardiovascular diseases. Donors were stratified by predonation body mass index (BMI) and by postdonation weight change. RESULTS: Obese donors (BMI ≥30 kg/m²) more frequently had pre-existing hypertension at baseline than non-obese donors (31.6% vs 18.3%, p = 0.03). During follow-up (median 2.9 years), 6% of living kidney donors developed arterial hypertension, 2.6% developed cardiovascular diseases and 1.1% developed type 2 diabetes mellitus. Obese donors had a higher incidence of postdonation type 2 diabetes mellitus than non-obese donors (p = 0.01). Changes in BMI postdonation were not correlated with age or predonation BMI. Donors with postdonation weight gain had slightly higher follow-up blood pressure, but no clear differences in rates of new-onset hypertension or type 2 diabetes mellitus were observed between weight-change groups. CONCLUSIONS: This exploratory analysis suggests that living kidney donation is generally metabolically safe. While metabolic changes were modest overall, obesity at the time of donation was associated with a slightly higher frequency of postdonation type 2 diabetes mellitus, underscoring the importance of counselling on lifestyle modification before donation.